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Abstract 
Objective: Dietary triggers such as gluten and highly fermentable oligo-, di- and 
monosaccharides and polyols (FODMAP) containing foods have been associated with worsening 
irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on 
IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review 
and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion 
diets (we focused on low FODMAP and gluten free diets (GFD)) in IBS.  
Methods: We conducted a search of the literature using the electronic databases MEDLINE 
(1946- November 2017), EMBASE (1974-November 2017), Cochrane Central Register of 
Controlled Trials (November 2017), Cochrane Database of Systematic Reviews (2005- 
November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened 
citations and a third reviewer resolved disagreement. Two independent reviewers performed 
eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet 
versus an alternative or usual diet, and assessed improvement in either global IBS symptoms or 
abdominal pain were required. Data were synthesized as relative risk of symptoms remaining 
using a random effects model. Quality of evidence was assessed using GRADE methodology.  
Results: 1726 citations were identified. After full text screening a total of nine studies were 
eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. 
Both selected patients that responded to a GFD and then randomized them to continue the diet or 
KDYHWKHGLHW³VSLNHG´ZLWKJOXWHQ$*)'ZDVDVVRFLated with reduced global symptoms 
compared with a control diet (RR 0.42; 95% CI 0.11 to 1.55. I2 = 88%), although this was not 
statistically significant. There were seven RCTs comparing a low FODMAP diet with various 
control interventions in 397 participants. A low FODMAP diet was associated with reduced 
global symptoms compared with control interventions (RR 0.69; 95% CI 0.54 to 0.88. I2  = 25%). 
The three RCTS that compared low FODMAP diet with rigorous control diets had the least 
heterogeneity between studies, but also the least magnitude of effect. The overall quality of the 
data was ³YHU\ORZ´ according to GRADE criteria.  
Conclusions: There is insufficient evidence to recommend a GFD to reduce IBS symptoms. 
There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms 
in IBS patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by 
symptoms of altered bowel habits (e.g. constipation and/or diarrhea), abdominal pain, and 
bloating without evidence of organic disease (1). The worldwide prevalence of IBS is 10-
20% (2) and it is associated with a significant reduction in quality of life, as well as anxiety 
and depression (3). A positive diagnosis of IBS can be made on symptom-based criteria (4) 
and there are a number of different therapies including manipulating the microbiome, 
pharmacological and psychological approaches (5). 
 
Pharmacological therapies can be effective, but surveys suggest that about 50% of patient 
with IBS use other approaches either in addition to, or instead of, conventional medical 
therapy (6), and over 60% report that particular foods trigger their symptoms (7, 8).  Patients 
with IBS are therefore often interested in exploring dietary interventions for their symptoms. 
It is important to give patients evidence-based advice on which diets may be effective in 
reducing their symptoms.  Initial approaches that based dietary recommendations for food 
sensitivities had disappointing efficacy in randomized trials (9), but recent dietary 
approaches have shown more promise.  It has been hypothesized that a subset of patients 
with IBS may have an intolerance of gluten, despite not having celiac disease (10). This has 
led some to recommend a gluten-free diet (GFD) in IBS. Another approach has been to 
reduce fermentable oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAPs) in the diet. This is the most widely adopted diet in IBS and may improve IBS 
symptoms (11). Systematic reviews of studies evaluating a GFD and a low FODMAP diet 
have provided conflicting conclusions (12, 13), but all have suggested more data are needed.  
Since publication of these systematic reviews, there have been additional randomized 
controlled trials (RCTs) evaluating exclusion diets in IBS (14, 15)  
The aim of this study was to conduct an updated systematic review of RCTs assessing the impact 
of a GFD or low FODMAP diet in improving IBS symptoms, in order to provide clinicians with 
an evidence-based assessment of the efficacy of both. 
 
Methods 
 
Search Strategy and Study Selection 
We conducted a search of the literature using the electronic databases MEDLINE (1946-
November 2017), EMBASE (1974-November 2017), Cochrane Central Register of Controlled 
Trials (September 2017), Cochrane Database of Systematic Reviews (2005- November, 2017) 
via OVIDSP for RCTS of exclusion diets in IBS (See Box 1 for eligibility criteria). We included 
abstracts and conference proceedings from Digestive Diseases Week (2014 to 2017). There were 
no language restrictions. We conducted the literature search as part of the American College of 
Gastroenterology¶V updated monograph on the management of IBS (in press). Search terms 
included ³LUULWDEOHERZHOV\QGURPH´³LUULWDEOHFRORQ´³JOXWHQIUHHGLHW´, ³JOXWHQIUHH´ ³IUXFWRVH
ROLJRVDFFKDULGH´³)2'0$3RU)2'0$3V´³GLHWrestriction´³IUXFWDQ´³FDUERK\GUDWHGLHW´, 
³VZHHWHQHU´HWFcombined with AND terms. Additional combined teUPVLQFOXGHG³FOLQLFDO
WULDOV´³GRXEOHEOLQGHG´ ³EOLQG´, or ³UDQGRPL]HGFRQWUROOHGWULDOV´, etc (for search strategy see 
appendix 1). We contacted authors for dichotomous outcomes if these were not reported, as well 
as for missing data. Two independent reviewers performed screening of citations and a third 
reviewer resolved disagreement. 
 Outcome Assessment 
The primary outcome was global improvement in IBS symptoms. If global improvement was not 
reported, we used abdominal pain as the outcome of interest. If different definitions of symptom 
improvement were provided in the same study, we used the most stringent outcome reported that 
minimized placebo response rate (e.g. an improvement in IBS symptoms of >50% would be 
chosen ahead of an improvement in symptoms of > 25%). Secondary outcomes included general 
quality of life and any occurrence of adverse events. 
 
Data Extraction 
Two independent reviewers (JD and YY) performed data abstraction. Data extracted (Table 4) 
included data on year of publication, country of origin, type of diet used, duration of 
therapy, primary and secondary outcomes used, IBS definition used (e.g., Rome criteria 
versus clinician diagnosis), the comparator intervention, and predominant stool pattern 
(constipation versus diarrhea) of recruited patients. Data were abstracted as an intention-to-
treat analysis, with drop outs treated as treatment failures. Disagreements were resolved by a 
third reviewer (PM). 
Assessment of risk of bias and GRADE Methodology  
The risk of bias assessment was performed by two independent reviewers using the Cochrane 
Risk of Bias Tool with ReviewManager (RevMan) (Version 5.3, Cochrane Collaboration). Each 
study was evaluated based upon reporting of randomization, allocation, blinding, and outcome 
assessment and reporting. Grading of the evidence was performed according to GRADE 
methodology using GRADEPro GDT (16).  
 Data synthesis and statistical analysis 
Data analysis was performed using RevMan 5 (Version 5.3, Cochrane Collaboration). We 
calculated relative risk (RR) with 95% confidence intervals of symptoms not improving in 
IBS compared with control. Data were pooled with a random effects model. Heterogeneity 
was evaluated with the I2 statistic, with >25% considered to be significant heterogeneity. 
We used forest plots with RRs for primary and secondary outcomes. Funnel plots were 
generated to assess for publication bias, if more than 10 studies were identified. Reasons 
for heterogeneity were explored using subgroup analyses. These include evaluation by low 
risk of bias trials versus unclear/high risk of bias, type of active dietary intervention, type 
of control intervention, definition of IBS, subtype of IBS according to predominant bowel 
habit, and setting.   
 
Results 
The literature search identified 1725 citations, and 72 studies underwent full manuscript review. 
After full text screening, 63 articles were excluded, leaving a total of nine studies eligible for the 
systematic review (Figure 1). 
 
Gluten Free Diet and IBS  
There were two RCTs (17, 18) of a GFD, involving 111 participants. Both selected patients that 
had already responded to a GFD, and then randomized them to continue the diet, or to have the 
GLHW³VSLNHG´ZLWKJOXWHQThe description of the trial characteristics is given in Table 1.  One 
trial (17) was low risk of bias, and the other (18) was of unclear risk of bias.  A greater 
proportion of participants had an exacerbation of their IBS symptoms among those allocated to 
have their diet spiked with gluten, compared with those remaining on a GFD.  Both trials 
reported a statistically significant result, but when the two trials were pooled the results were not 
statistically significant (RR = 0.42; 95% CI 0.11 to1.55, I2 = 88%) due to the marked 
heterogeneity between individual trial results (Figure 2). Neither study reported on adverse 
events or general quality of life. 
 
Low FODMAP Diet and IBS 
There were seven RCTs (14, 115, 19-23) comparing a low FODMAP diet with various control or 
control comparator interventions in 397 participants. A summary of the trial characteristics is 
given in Table 1.  There were no low risk of bias trials, and this was mainly due to lack of 
blinding.  More recent studies have made excellent efforts to maintain blinding (14) but we 
classified studies as not blinded as the contents of a low FODMAP diet are readily available on 
the internet and on cell phone applications. A low FODMAP diet was associated with a reduction 
in global symptoms compared with controls (RR 0.69; 95% CI 0.54 to 0.88, I2 = 25%) (Figure 3).  
One trial (14) reported general quality of life, with no difference between the two groups (mean 
difference = 1.30; 95% CI = -6.82 to 9.42).  Two trials reported on adverse events (14, 15) but 
did not present data that could be extracted.  Both trials reported that diets were well tolerated 
with no serious adverse events.  
 
We explored reasons for heterogeneity between studies using subgroup analyses and the largest 
contributor to this was the choice of comparator diet with 52% of the variation in effect size 
between subgroups not due to chance (Figure 3). 
 Low FODMAP versus an Alternative Diet 
Three studies (14, 15, 19) examined a low FODMAP versus an alternative diet encompassing 
271 patients. There was a trend for a low FODMAP diet to reduce global IBS symptoms 
compared with alternative diets (RR = 0.82; 95%CI = 0.66 to 1.02) but this was not statistically 
significant. 
 
Low FODMAP versus High FODMAP Diet 
Only one study by McIntosh et al. (20) compared a low FODMAP with a high FODMAP diet in 
40 patients. This study also found that a low FODMAP diet led to a reduction in global IBS 
symptoms compared with a high FODMAP diet (RR = 0.44; 95% CI = 0.23 to 0.83).  
 
Low FODMAP versus Usual Diet 
Two studies evaluated a low FODMAP diet versus a usual diet (21, 22) and included a total of 
71 patients.  There were fewer patients with persistent IBS symptoms in the low FODMAP diet 
arm, compared with a usual diet (RR = 0.46; 95% CI = 0.25 to 0.84). 
 
LOW FODMAP exclusion followed by LOW FODMAP challenge versus placebo 
Hustoft et al. (23) implemented a low FODMAP diet and 15 patients that responded to the diet 
were subsequently randomized to receive a supplement, either a placebo or one containing a 
FODMAP. Patients receiving placebo maintained the reduction in their IBS symptoms compared 
with placebo, but this small study was not statistically significant (RR = 0.44; 95% CI = 0.11 to 
1.71). 
 Risk of Bias and GRADE 
The overall quality of the data was ³very ORZ´ according to GRADE criteria (Table 2 and Table 
3) as most studies were unclear or high risk of bias, there was heterogeneity between study 
designs, and there was imprecision in the estimate of effect. 
 
Discussion 
The management of IBS should be evidence-based and any therapy should ideally be supported 
by high quality RCTs.  For many years, this had been lacking for dietary interventions in IBS, 
with only three eligible RCTs identified in our last systematic review on this topic (13).  There 
has been an increase in the quantity and quality of RCTs evaluating dietary therapies for IBS in 
recent years and this systematic review identified 11 RCTs, involving 508 participants, 
evaluating either a low FODMAP diet or a GFD.  We found there was insufficient evidence to 
recommend a GFD, but there was very low quality evidence to support recommending a low 
FODMAP diet in IBS.  A further RCT (24) suggested any benefit of GFD may relate to the 
reduction in FODMAPs consequent on this dietary change.   
Proponents of a low FODMAP diet for IBS may be disappointed that the quality of the evidence 
is not rated higher.  We used GRADE methodology (25) to evaluate the quality of the evidence, 
which is the most widely accepted approach, and one that is used by over 100 organizations 
throughout the world. The reason for the very low quality rating is the different comparator 
groups used in individual trials, and the relatively modest numbers of patients with an 
improvement in global IBS symptoms. Specifically, there were only a total of 189 participants in 
the low FODMAP diet trials who experienced an improvement in their symptoms, whereas 
GRADE would ideally require 300 events for data to be classified as robust (26).  These factors 
could be improved with further trials using similar comparators and providing more data, 
although this is a challenge given there is no pharmaceutical industry support and most federal 
funding agencies do not rate IBS as a priority area for research funding.  Indeed, researchers in 
this area should be congratulated on the number of participants they have recruited to RCTs to 
date, despite these challenges.  The area that will be more difficult to address is the issue around 
lack of blinding.  Many IBS patients are aware of the concept of a low FODMAP diet, and 
information on this diet is freely available.  An IBS patient can, therefore, easily deduce which 
diet they have been allocated to if they participate in an RCT.  Asking the participant which 
JURXSWKH\WKLQNWKH\KDYHEHHQUDQGRPL]HGWRVRWKHSURSRUWLRQZLWKLQFRUUHFW³JXHVVHV´FDQ
be calculated) may not identify this problem as participants that have identified which group they 
were allocated to may not admit to this.  The only robust approach would be a double-blinded 
challenge study, where everyone is placed on a low FODMAP diet and then randomized to 
continue on that diet or have their diet spiked with a high FODMAP product.  Even this is 
challenging to interpret, as any change in diet, even if it is unrelated to IBS, can cause 
gastrointestinal symptoms as the GI tract is exposed to new foods. In addition, even brief dietary 
interventions can change the gut microbiome, making rechallenge studies difficult to interpret. 
Ideally, challenge studies should, therefore, be long term in order to account for any short-term 
non-VSHFLILFHIIHFWVRIIRRGVWKDWWKH*,WUDFWKDVQRWH[SHULHQFHGUHFHQWO\'HILQLQJ³ORQJWHUP´
is a challenge in this context, but we would suggest at least 8-12 weeks of follow up and all 
studies in this review were of a shorter duration. 
Providers recommending the low FODMAP diet should bear in mind that exclusion of 
FODMAPs is only the first phase of the diet program. Exclusion for 2-6 weeks should be viewed 
as a diagnostic test to identify IBS patients who are sensitive to FODMAPs. Those who fail to 
improve should not continue the diet. Those that improve should be instructed on reintroducing 
foods which contain FODMAPs to determine their sensitivities. This information should then be 
used to liberalize and personalize the low FODMAP diet with the intention of improving 
adherence and minimizing effects on the gut microbiome.  
There is much less data for a gluten-free diet or elimination diets based upon IgG antibody 
testing. As has already been pointed out, there is little to no data which addresses the long term 
efficacy, adherence, or harms of diet therapies for IBS. Recommendations regarding other diets 
(e.g. dairy-free, lactose-free, vegetarian, etc.) cannot be made due to lack of objective 
information. Regardless of the gaps in the data, it is clear that diet therapies are here to stay. The 
complexity of diet therapies for IBS, potential for inducing nutritional deficiencies, and time and 
resources required to provide proper counseling provides tangible incentives to utilize a properly 
trained dietician. If a trained dietician is not available or a patient cannot afford to see a dietician, 
it is important for providers to have assembled high quality teaching materials which can allow 
an IBS patient to implement diet therapy in a medically responsible manner. 
Overall, the sample size within each trial was small and some studies utilized a cross-over 
design. These two factors raise concern regarding the external validity of the results, given the 
high prevalence of IBS within the general population, but relatively small sample sizes recruited 
in the current studies. Further studies could elucidate factors that limit study enrolment. In 
addition, future studies should utilize a parallel RCT design rather than a cross-over RCT 
methodology for a common disorder.  The main reason for this is that we do not know the 
mechanism by which exclusion diets may reduce symptoms in IBS.  It could relate to the direct 
effect of the food, such as osmotic load to the intestine, a subtle immune response to a certain 
food group, or an influence on the gut microbiome that leads to GI symptoms (27).  As we do not 
know the mechanism, it is difficult to recommend a definitive wash-out period, and, therefore 
cross-over trials should be avoided.  RCTs could further improve our knowledge of how 
exclusion diets may impact on IBS by collecting mechanistic, as well as symptom, data.  Indeed, 
some of the trials did collect microbiome and metabolomics data (14, 20).  Studies rarely 
reported on general quality of life or adverse events and it would be important for future trials to 
address this deficit.  Exclusion diets may have nutritional implications for patients or adversely 
impact on the microbiome, so it would also be important to evaluate long term safety concerns 
with a low FODMAP diet. 
 
This study has several strengths.  We used robust systematic review methodology and rigorously 
evaluated the quality of the evidence.  The number of eligible studies has also increased 
significantly since this topic was last evaluated.  There are, however, a number of limitations to 
this systematic review.  As stated above, more events are needed before results can be considered 
robust, and there was variation in the comparator diet between trials.  Freely available 
information on the low FODMAP diet is an issue for adequate blinding, and if new diets are 
developed in the future it would be advisable to keep them as confidential as possible until 
sufficient RCT data are collected.  Finally, there was insufficient information to evaluate whether 
GFD or low FODMAP diet was more effective in certain subgroups of IBS patients, such as 
those with predominant diarrhea or bloating.      
 
The findings of this review demonstrate that, at present, there is insufficient evidence to 
recommend a GFD to reduce global IBS symptoms. There is very low quality evidence that a 
low FODMAP diet is effective in reducing global symptoms in IBS patients. More data are 
needed, but of the available dietary interventions, a low FODMAP diet currently has the greatest 
evidence for efficacy in IBS. 
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